A new publication dated October 28, 2026 discusses pramlintide in the context of type 1 diabetes therapy. The article, titled "Beyond Insulin Therapy: Therapeutic Potential of Alpha-glucosidase Inhibitors in Type 1 Diabetes Mellitus," appears in the journal Mini Reviews in Medicinal Chemistry. The publication is listed under PubMed ID 42983241. This is a review article addressing therapeutic approaches in type 1 diabetes mellitus beyond standard insulin treatment. Pramlintide is an approved compound referenced within this review. No specific findings, data, or conclusions from the publication have been provided beyond its title and journal placement. Readers interested in the broader context of this topic can consult the full publication directly through the listed source. For general background on pramlintide, its approved status, and its role in diabetes management, readers can refer to the compound overview.
Pramlintide Referenced in New Review on Type 1 Diabetes Therapies
See the full pramlintide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42983241/